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SUMMARY 
Background: Tuberculosis (TB) is a major cause of morbidity and mortality worldwide. TB kills 2 
million people each year and 98% of these deaths occur in developing countries. TB remains a 
burden especially in Africa, Eastern Mediterranean and South-East Asia regions. 
 Among 22 countries with the highest TB burden in the world, Tanzania ranks as number 14 
globally and is the 6th in Africa. The number of TB cases in Tanzania has increased six folds in the 
past two decades. Case detection rate in Tanzania is still below the global estimated target of 70%. 
Seven percent of the population in Tanzania is infected with HIV and 50% of TB patients are co-
infected with HIV. In addition, the majority of TB patients are malnourished. 
Because resources are limited, it is imperative to focus the efforts of the health system on those 
patients needing the most care. Lack of sputum conversion in pulmonary tuberculosis patients on 
anti-TB treatment is an indicator of potential treatment failure. These patients represent a source 
of continued TB transmission. Such patients may in the worst case turn out to be harbouring drug 
resistant Mycobacterium tuberculosis. 
Predicting treatment outcome in TB patients receiving anti-TB treatment at an early stage, by 
identifying factors among patients who are more likely to end up in treatment failure, would 
benefit the TB program overall and allow the TB staff to take special care of those patients who 
could be at an increased risk of not sputum converting at the end of the 2nd month of the intensive 
phase of anti-TB treatment. The aim of this study was to identify risk factors that may be 
associated with persistent sputum smear positivity at the end of the 2nd month after initiation of 
anti-TB treatment among pulmonary TB patients in Mwanza, Tanzania.   
Methods: A prospective cohort study conducted within ongoing randomised multi-micronutrient 
supplementation trials among smear positive pulmonary TB patients in Mwanza city was 
undertaken from April 2006 to November 2008. All patients recruited were interviewed to obtain 
social demographic and TB medical history. In addition, anthropometric measurements (height, 
weight, and arm circumference and body mass index [BMI]) were recorded at baseline and at 2 
months post initiation of anti-TB treatment. HIV counselling followed by HIV testing was 
undertaken for all patients. Laboratory investigations for CD4+ count, white blood cell count
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 (WBC), haemoglobin (Hb), sputum smear microscopy and sputum culture were undertaken. 
Results: A total of 601 PTB patients were enrolled of which 249 (41%) were HIV+. Five hundred 
and sixteen (86%) patients were followed to the end of the 2nd month anti anti-TB treatment. The 
overall sputum smear conversion rate at the end of the 2nd month of the intensive phase was 76. 
4%, while the sputum culture conversion rate was 94. 2%. Factors associated with persistence of 
sputum smear positivity at the end of the 2nd month of intensive phase were: male sex (OR 1.92, 
95%CI 1.16; 3.18, P=0.01), 3+ initial pre-treatment AFB smear grading (OR 1.9, 95%CI 1.17; 
3.19, P=0.01) and a BMI of < 18.5kg/m2 (OR 2.17, 95%CI 1.24; 3.7, P=0.006). The presence of a 
BCG scar was found to be associated with a 43% lower risk of persistence of sputum smear 
positivity at the end of the 2nd month after initiation of anti- TB treatment (OR 0.57, 95%CI 
0.35;0.95, P=0.032). The presence of a BCG scar was also strongly associated with a lower risk of 
persistent sputum culture positivity (OR 0.28, 95%CI 0.35; 0.95, P=0.002). HIVstatus, smoking, 
CD4 count, total WBC count and Hb levels were not significantly associated with sputum smear 
microscopy and sputum culture conversion post anti-TB treatment. 
 Conclusion: Pulmonary TB patients with an absence of BCG scar, male sex, high initial AFB 
sputum grading, and a low body mass index, are at a risk of remaining culture and/or sputum 
smear positive at the end of 2nd month of the intensive phase of anti-TB treatment. Closer 
attention should be provided to such patients while on anti- TB treatment. Additionally, BCG 
vaccination should be continued to be promoted and supported. Larger studies also in other areas 
are needed to assess the role of BCG vaccination on sputum conversion.
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1.0 INTRODUCTION  
1.1. TB natural history 
Tuberculosis (TB) is an airborne disease caused by Mycobacterium tuberculosis (M.tb), an 
organism that was discovered by a German physician Robert Koch in 1882 (1). TB is a disease 
that affects a number of different organs of the human body, but primarily the lung. The mode of 
spread is from an infected person to an uninfected person by inhalation of infected droplet nuclei 
with M.tb. 
The period from which a person is infected by M.tb up to the development of active disease varies 
from individual to individual (2, 3). The development of infection to active disease can take many 
years, or the infection may remain dormant for life. Only 10% to 20% of all individuals who are 
infected with M.tb end up with active disease in their life time (2, 3).  
Common clinical presentations of pulmonary TB (PTB) include, coughing more than two weeks, 
fever, night sweat, haemoptysis and wasting (4). The health status of an individual is an important 
determinant for the risk of progression to TB disease. The progress of the disease depends mainly 
on tissue destructive delayed-type hypersensitivity reaction to M.tb and cell mediated immunity 
(macrophage-activating responses). In general, type 1 T helper cells provide protective immunity 
while type 2 T helper cell response leads to tissue destruction. Following infection, TB may either 
progress to disease immediately (like infants or severely immunosuppressed individuals) or the 
bacteria may be contained by the immune system. This progress phenomena  theoretically is 
divided into primary and post-primary forms and both have quite different  pathological features 
(5). Following an initial infection, the inhaled mycobacteria via the respiratory tree reach the 
alveoli where they are engulfed by alveolar macrophages, which comprise the initial lesion (Ghon 
focus). If the initial defence fails to contain the bacteria, M.tb continues to multiply intracellularly 
leading to cavity formation. Once a cavity is formed a large number of bacilli are excreted in the 
sputum and a patient becomes an infectious case. Twenty per cent of cases of open cavitating TB 
resolve without treatment (5). 
1.2. TB burden 
Despite the existence of TB control programmes globally, TB remains one of the major 
publichealth problems worldwide. It is one of the greatest challenges that face health systems in 
the 21st century. The total numbers of new TB cases is rising worldwide. From 1997 to 2000 the 
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number of new TB cases increased at a rate of 1.8 % per year (3). They were an estimated 
 8.3 million new cases in 2000 and the number rose up to 9.2 million in 2006 (3, 6, 7). The most 
affected region is, Africa which accounts for 31% of the global TB cases while the western pacific 
and South-East Asia regions together account for 55% (6-8). In sub-Saharan Africa, the TB 
incidence rate is twice that of the South East Asia region at nearly 350 cases per 100,000 
population (8). 
Tanzania ranks 14th among the 22 countries with the highest TB burden worldwide and 6th in 
Africa (6, 7). The case detection rate in Tanzania is still below the global estimated target of 70 % 
(6, 7). The majority of the cases appear to be in young adults aged 15-45 years, the same age 
group that is affected by HIV/AIDS (3, 9). Approximately, 50% of all TB patients in Tanzania are 
co-infected with HIV (9). TB cases in Tanzania have increased from 11,753 in 1983 to 65,665 in 
2004 (9). This increase is largely attributed to HIV/AIDS (9). It is estimated that
 
about 7% of the 
general population in Tanzania is infected with HIV (10). The life time risk to develop TB in HIV 
negative individuals is 5-10% compared to 50% in HIV positive individuals (9).  
1.3. TB and HIV interaction 
TB and HIV are difficult to separate from each other as both have an impact on one another. 
While HIV increases the risk of developing active TB, TB on other hand adds to the risk of 
progression from HIV to AIDS (8). Dual infection with HIV/AIDS and TB has contributed largely 
to an increase in number of new TB cases worldwide and remains a major cause of death in an 
HIV infected person (7, 9). The African region has 85% of all TB cases with HIV (7). South 
Africa has 28% of all TB/HIV case globally and contributes 33% of all cases in Africa (7). Data 
from East Africa shows Kenya to contribute 10% of all HIV/ TB cases while Tanzania has 3% 
and Uganda 2% (7). TB patients co-infected with HIV are at risk for a poor treatment outcome 
(11). Sputum conversion at two months post anti-TB treatment has been reported to be important 
interim indicator of treatment success (12). A cohort study conducted in North Carolina, U.S.A. 
reported HIV infection as one of the important predictors of lack of sputum conversion in TB 
patients (11). The study showed that 46% of TB patients co- infected with HIV had a lower rate of 
sputum conversion compared to non-HIV infected TB patients (11). A study from Uganda, 
undertaken by Bwire et al showed no difference in sputum conversion rate at 8 weeks post anti-
TB treatment in TB patients with HIV and those without HIV (78% vs.76%), however TB  
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with HIV were more likely to die (P=0.017) (13). 
1.4. TB and nutrition  
Malnutrition has also been associated with increasing susceptibility to TB. Studies have shown TB 
patients suffer from wasting and micronutrient deficiency (14). Concurrent macro and 
micronutrient deficiency compromises the immune system function which in turn increases the 
risk of TB reactivation (15). A study conducted to assess nutritional status between TB patients 
and healthy controls, showed that 66% of the TB patients were underweight as compared to 10% 
of the healthy controls (P<0.001) (16). Furthermore, the study also showed that the plasma retinol 
concentration in TB patients was lower than that for healthy individuals (16). Vitamin A 
deficiency has been shown to be a risk factor for developing TB (17). Various mechanisms like, 
poor dietary intake due to loss of appetite, poor absorption of nutrients from the intestine and 
increase uptake of nutrients by specific target tissue due to increase body metabolism, were 
associated with nutritional deficiency in TB patients (17). Since anti-TB treatment is given to 
malnourished TB patients, there is a possibility that nutritional deficiency may impair treatment 
outcome. A study from Indonesia by Karyadi et al reported that micronutrient supplementation 
resulted in an earlier elimination of tubercle bacilli from the sputum (18). The number of patients 
with sputum smears negative for tubercle bacilli were higher in the micronutrient supplemented 
group than in the placebo group (23% vs. 13%) (18). However, a recent study conducted in 
Mwanza, Tanzania on the effect of micronutrient supplementation on treatment outcome in PTB 
patients showed that neither multi-micronutrient nor zinc supplementation had a significant effect 
on sputum culture conversion, although multi-micronutrient supplementation was significantly 
associated with the weight gain (0.78 kg; P=0.02) (19). 
1.5. Laboratory diagnosis and treatment  
TB case identification depends on availability of sensitive and specific diagnostic tools. A part 
from presumptive diagnosis of TB based on clinical symptoms and chest x-ray findings, a 
definitive diagnosis of TB relies upon the identification of the causative agent in clinical samples. 
Detection of M.tb in clinical specimens can be undertaken by various methods such as 
microscopy, culture, and the newer polymerase chain reaction (PCR) based assays. The 
commonest method in use for diagnosing TB cases is still sputum examination by microscopy in 
high TB burden countries. Microscopy is cheap, easy to perform and does not require highly 
skilled technicians. Despite being widely used, microscopy has limitations as it is not specific for 
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the detection of acid-fast bacilli (AFB) in sputum and can only detect AFB in 60-70% of culture 
positive specimens (20, 21). Ziehl-Neelsen staining (ZN stain) and fluorescent staining are the 
current microscopic methods in use. ZN microscopy is still widely used in low and middle income 
countries as it is relatively cheap. Fluorescent microscopy is more sensitive and is faster thereby 
decreasing the time required to examine slides although the related expenses do limit its wide use 
(21).  
Culture remains the cornerstone of TB diagnosis. Compared to microscopy, culture is more 
sensitive as it can detect as few as 10 bacteria per ml of sputum and it has a sensitivity of 80-85% 
and specificity of 98% (22). Despite the benefit that culture methods have, the cost and time taken 
to obtain a result (4-8 weeks) limit their wide spread use. Apart from the methods mentioned, 
there are other rapid diagnostic methods which are relatively expensive and thus are not affordable 
in high TB burden countries. These include DNA and RNA based PCR methods. Newer 
commercially available bloods test (Quantiferon, TB-Gold in tube - Cellestis, T-spot.TB - Oxford 
immunotec) that measure interferon gamma responses to M.tb specific antigens are also being 
promoted. These tests do not accurately distinguish active TB disease from latent infection (4, 5). 
Large prospective longitudinal studies are required to assess the diagnostic and prognostic value 
of these interferon gamma release assays (IGRAs). 
An identified case of active TB needs to be treated appropriately in order to stop the chain of 
transmission. Anti-TB drugs are either bactericidal or bacteriostatic. The bacteriostatic drugs are 
not included in standard drug regimens of TB treatment. The anti-TB drugs which are bactericidal 
can effectively sterilize the TB lesion. World Health Organization (WHO) promotes a 
combination of different anti-TB drugs in order to prevent the emergence of drug-resistant strains. 
The current regime in the management of TB is divided into 2 months of intensive phase and 4 
months of continuation phase of anti-TB therapy. During the intensive phase, the drugs in use are 
rifampicin, isoniazid, pyrazinamide and ethambutol. Usually in the first and second week 
following the initial infection there are large numbers of actively replicating bacilli present in the 
pulmonary cavities. Most bacilli are initially killed by isoniazid with the help of rifampicin and 
ethambutol. These drugs quickly render the patient non- infectious. In the following weeks of the 
intensive phase the remaining bacilli are killed by pyrazinamide and rifampicin. In the 
continuation phase the main drugs used are rifampicin and isoniazid. All remaining dormant 
bacilli are killed by rifampicin and those that are rifampicin- resistant are killed by isoniazid (5).
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1.6. TB control strategy in Tanzania 
TB control in Tanzania is performed by the National Tuberculosis and Leprosy Programme 
(NTLP). Formulation, policy development and implementation is undertaken at the central level in 
line with guidelines developed by WHO and other related partners. At the regional level 
TB/leprosy coordinators interpret policy guidelines and monitor implementation at the district 
level. The NTLP under the Ministry of Health and Social Welfare (MOHSW) has successfully 
extended activities to include TB/HIV control in the whole country. The TB case detection rate 
was 46% and treatment success rate 82 % in 2005 (7). 
1.7. Indicators of TB treatment success 
Early case identification and treatment of all TB cases is a priority. It has been shown that sputum 
smear conversion is an important indicator of both the effectiveness of treatment and infectivity of 
the patients (23). Persistent smear positivity at the end of the 2nd month of treatment has been cited 
as one of the main predictors for treatment failure (23, 24).
     
                     
Various studies have been undertaken in different settings to identify factors associated with 
sputum conversion. It has been shown that factors like an initial pre-treatment high sputum AFB 
smear grading is associated with persistent sputum positivity at 2 months post anti-TB treatment 
(25). Cure rates and conversion rates decrease as initial smear grading increases (26). Thus, a 
study conducted in Thailand showed that sputum conversion after 2 months of the intensive phase 
was 61.7% in patients with pre-treatment strongly positive smears (grading 2+ or greater) 
compared to 91% in patients with weakly positive smears (grading less than 1+) (27). A study 
undertaken in Gambia showed that the proportion of smear converters at 2 months was inversely 
related to the bacterial load in the initial sputum smear (96.2%, 85.8% and 81.8% for initial smear 
grading of 1+, 2+ and 3+ respectively P<0.001) (28).  
Other findings from studies assessing predictors for sputum conversion show factors such as, age 
of the patient, duration of smoking, and gender, may have significant impact on sputum 
conversion (23, 25, 29). A study undertaken to identify, simple clinical, microbiological and 
radiological factors that were associated with a delay in sputum sterilization in Saudi Arabia, 
showed that age above 40 years was significantly associated with persistent sputum smear 
positivity (24). In another study from Guinea Bissau using a simple clinical score based system to 
measure a TB patient’s clinical status at repeated visits, showed that 21% of mortality occurred in 
  
 
 
     
 
6 
patients with a higher score compared to 13% mortality in patients with a low score (30). 
The cluster differentiation antigen 4 (CD4+) counts, are important in monitoring the immune 
system in TB patients co-infected with HIV, however, CD4+ counts together with Hb in TB 
patients have not been shown to be among significant factors predicting sputum conversion (29). 
Other blood parameters like platelet levels and erythrocyte sedimentation rate have been shown to 
be significantly associated with time to sputum conversion (25, 29).   
2.0 RATIONALE 
Predicting treatment outcome among TB patients receiving anti-TB treatment under directly 
observed treatment short course (DOTS) strategy helps in recognizing cases that are more likely to 
fall in the treatment failure group. In Tanzania, a routine procedure used for diagnosing new PTB 
cases is sputum smear microscopy. The approach in which every suspected TB case should submit 
3 sputum specimens for smear microscopy examination, detects up to 80% of smear positive 
patients on first specimen examination. Fifteen percent of smear positive patients can be detected 
on a second sputum specimen examination and 5% on the third sputum specimen (9). In 2006, 
Tanzania introduced a change in the short course treatment regimen for TB under the DOTS 
strategy. The change in treatment regimen goes hand in hand with changes in the diagnostic 
sputum submission procedure from 3 samples of sputum specimens to only 2 samples, one 
produced on the spot and one morning sputum specimen on the following day. The short course 
regimen for 8 months was discontinued and switched to a 6 months short course regimen. The 
new regimen is divided into 2 months of intensive phase and 4 months of continuation phase. In 
this regimen drugs are given to patients in a fix dose combination (FDC) of 4 drugs (rifampicin, 
isoniazid, pyrazinamide and ethambutol) during the 2 months of intensive phase and 2 drugs in a 
FDC (rifampicin, isoniazid) during the 4 month of continuation phase (9). In general, anti-TB 
drugs are effective and most TB patients are cured. However, it is a challenge that some patients 
fail to convert after anti-TB treatment, the so-called treatment failure patients. Various studies in 
different settings worldwide have tried to identify factors that may be associated with sputum 
conversion. Many factors such as clinical, microbiological, radiological and social demographic 
factors may be associated with sputum smear and culture conversion. Little is known about factors 
that may be associated with persistent sputum AFB positivity in Tanzania. With this objective in 
mind, we undertook a prospective study among sputum smear positive PTB patients in Mwanza, 
Tanzania. Factors that could be associated with persistent sputum positivity at the end of 2 months 
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after initiation of anti-TB treatment were assessed. Delineating factors associated with delayed 
sputum conversion could help in strengthening TB control programmes, especially in a low 
income country like Tanzania. 
 
3.0 OBJECTIVES OF THE STUDY 
3.1. Study goal 
To improve TB treatment outcome in Tanzania 
3.2. General objective 
To assess the role of HIV and other predictors of sputum smear and culture conversion at 2 
months following initiation of anti-TB treatment among sputum smear positive PTB patients.  
3.3. Specific objectives 
1. To determine the sputum smear and culture conversion rates at the end of 2 months after   
            initiation of anti-TB treatment. 
 
2. To determine the relationship between AFB smear and culture grading at baseline and  
             sputum conversion at the end of 2 months after initiation of anti-TB treatment. 
 
3. To determine the relationship between HIV status and CD4+ counts at baseline and  
             sputum conversion at the end of 2 months after initiation of anti-TB treatment. 
 
4. To assess the effect of anthropometric (BMI, arm circumference), and bio-chemical  
             parameters (Hb, WBC count) on sputum smear conversion (at the end) of 2 months after  
             initiation of anti-TB treatment.
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4.0 METHODOLOGY 
4.1. Study setting and design 
 4.1.1. Study setting 
The study was conducted in the city of Mwanza which is constituted by two districts namely 
Ilemera and Nyamagana. Mwanza city is the second largest in Tanzania after Dar es Salaam. 
Mwanza city is located on the southern shore of lake Victoria in the northern part of Tanzania 
(Figure.1). It covers an area of 1,325 sq km of which 425 is dry land and 900 sq km is covered by 
water from Lake Victoria. Of the 425 sq km dry land area, only 86.8 sq km is urbanized. 
According to the 2002 National census, Mwanza city has a total population of 476,646 
(Nyamagana District 210,735 and Ilemera 265, 911). The current population is estimated to be 
just above half a million people, with an annual growth rate of 3.2%. Rural to urban migration is 
approximately 8% (31). 
Mwanza city is divided by the NTLP into 3 operating TB districts. These are Mwanza urban 
North, Mwanza urban East and Mwanza urban South. These 3 NTLP districts cover the entire 
Mwanza city. Mwanza city has a TB notification rate (smear positive) of 50-100 per 100,000 (32). 
Daily TB clinic services in the city are provided by both the government and private hospitals. 
Each district has at least one main health facility where TB patients are registered after being 
diagnosed with TB at a nearby clinic. The health facilities at each district are Bugando Medical 
Centre and Butimba health centre for Mwanza urban South district. Buzuruga health centre for 
Mwanza urban East district, and Sekou- Toure regional hospital for Mwanza urban North districts. 
Together these health facilities provide health services to inhabitants of Mwanza city. and those 
from outside Mwanza city. 
4.1.2. Study design  
A prospective cohort study conducted within ongoing randomised clinical trials.
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Figure 1. Map of Tanzania showing the location of Mwanza city 
 
4.2. Study population 
All patients diagnosed with sputum smear positive PTB recruited from the 3 NTLP districts and 
attending the four major health facilities from April 2006 to November 2008 in Mwanza city were 
considered for recruitment. Sputum smear positive PTB patients who consented and were 
participating in the ongoing randomised nutritional supplementation trials in Mwanza and met the 
inclusion criteria, were recruited. The ongoing randomised nutritional supplementation trials are 
aimed at evaluating the effect of energy protein and micronutrients supplementation on various 
TB treatment outcomes. The trials commenced in 2006 in Mwanza city, in which patients who 
were diagnosed to be smear positive PTB with HIV were randomised to either biscuits containing 
multi-micronutrients (MMN) with high or low energy-protein (E-P). Patients who were diagnosed 
as smear positive PTB without HIV, were randomised to receive one E-P biscuit with or without 
MMN (Figure 2).
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Figure 2. A profile of trial participants receiving either the multi-micronutrient (MMN) or the 
energy-protein (E-P) intervention 
 
 
 
4.3. Inclusion and Exclusion criteria 
4.3.1. Inclusion  
1. Sputum smear positive PTB patients recruited at the local health facilities and confirmed 
as sputum smear positive at the Zonal reference laboratory. 
2. Patients aged 15 years or above. 
4.3.2. Exclusion  
1. Pregnant women. 
2. Terminal illness (from TB or any other serious infection unlikely to survive more than 48  
hours). 
3. Non – residence (patients who will not stay in the study area for the entire period of six  
months for anti -TB treatment). 
4. Not willing to participate.       
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4.4. Sample size 
All consecutive smear positive PTB patients confirmed as smear positive at Zonal tuberculosis 
reference laboratory (ZTRL) from April 2006 to November 2008 were recruited. For calculating 
the sample size the proportion of patients that failed to convert by sputum culture at the end of 2nd 
months of the intensive phase was assumed to be 14% in Mwanza city (19). The absolute 
estimated precision of the proportion of sputum culture non-converters was set to be 0.03 i.e. its 
95% confidence interval was targeted to be 0.05.  
 
The following formula was used for sample size calculation. 
n= (Z1-α/2)2 x p x (1-p)/d2   
Where: 
n = required sample size 
Z = reliability coefficient (1.96) 
p = estimated proportion of sputum culture non-conversion among sputum culture positive PTB 
patients in Mwanza city (14%) 
d = absolute estimated precision error required on either side of proportion (0.03) 
n= (1.96)2 x 0.14 x (1-0.14)/0.032 =514 
 
The sample size was increased by a factor of at least 15% to compensate for those who could be 
lost to follow up, for those with negative culture results at baseline, for contaminated culture 
results and for those who could die before the 2 months visit. From April 2006 to November 2008 
a total of 601 smear PTB patients were recruited. 
4.5. Patient enrolment, data collection and follow up procedure 
4.5.1. Patient enrolment procedure 
A total of 601 PTB patients who were smear positive regardless of their HIV status were enrolled 
into this study. Patients diagnosed as sputum smear positive by microscopy using Ziehl Neelsen 
staining at the first visit at a diagnostic health facilities, were referred to any of the  four main  
recruitment health facilities. At the recruitment health facility, patients were provided information 
on the study and those who were eligible and willing to participate
  
 
 
12 
 
 were asked for an oral and written consent. Those who consented and for whom one or both spot 
and next day early morning sputum samples were ZN smear microscopy positive, were requested 
to provide an additional early morning sputum specimen. The early morning sputum specimens 
were collected in sterile universal bottles and sent to ZTRL for smear microscopy examination 
using Auramine O staining and for culture using Lowenstein- Jensen solid media. Sputum results 
for AFB were graded at the ZTRL according to the WHO/IUATLD recommendations (9). Smear 
result was reported as “0” if there were no AFB seen per 100 fields, “1-9” if exact number of AFB 
seen per 100 fields, “1+” if AFB seen were 10-99 per 100 fields, “2+” if AFB seen per field were 
1-10 and “3+” if AFB seen per field were more than 10 per field (9). Regarding culture results, 
grading was reported as “0” if no growth, “1+” growth between 1-100 colonies; “2+” more than 
100 colonies but non confluent growth and “3+” confluent growth (19). Only PTB patients who 
were sputum smear positive by microscopy at both local health facilities and at the ZTRL were 
recruited into the study. 
4.5.2 Data collection procedure 
Participant’s information was collected through structured questionnaires at the first visit, and at 
the end of 2nd month after initiation of anti-TB treatment (see appendices). Information on social 
demographic characteristics was ascertained only at the first visit. Information such as medical 
history, smoking history and anthropometric measurements (height, weight, arm circumference) 
were collected at baseline and at the 2nd months visit. Patients’ weight, height, and arm 
circumference were measured using a digital weighing scale, height board and tape measure, 
respectively. Body mass index was calculated by dividing weight over height square.  
Additionally, HIV counselling and testing was done on all recruited participants. Participants were 
then requested to provide blood for a HIV test, total lymphocyte count (TLC) and CD4 cell counts. 
Ethylene diamine-tetra-acetic acid (EDTA) tubes were used to collect blood for Hb, WBC counts, 
and CD4 counts while plain vacutainer tubes were used to collect blood for the HIV test. Blood for 
HIV testing and other blood parameters were examined on the same day as collection at the 
National Institute for Medical Research (NIMR) laboratory. HIV testing was done using 2 
different rapid antibody tests; Determine HIV-1/2 (Inverness Medical Japan co ltd, Abbot, Japan) 
and Capillus HIV-1/2 (Trinity Biotech, Ireland). Discordant samples were tested using Uniform II 
vironostika-HIV Ag/Ab Micro-Elisa system (Biomerieux bv, The Netherlands). CD4+ counts
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were measured using a Partec cyflow counter machine (Germany). TLC counts were determined 
manually by a senior laboratory technician. 
 4.5.3 Follow up 
All patients that were seen at baseline were reviewed again at the end of the 2nd month post anti-
TB treatment. Information that was collected at baseline was repeated at 2 months except for 
social demographic information and HIV testing. 
4.6. Data management and analysis                   
Patient information was double-entered using EpiData version 3.1 and the data were analysed 
using STATA program version 10.1. The differences in proportions between groups were 
compared using chi–square test. Student t -test was used to compare the differences in means of 
continuous variables. Evaluation of risk factors of non-conversion by sputum smear and culture 
examination at the end of the 2nd month of intensive phase was undertaken by logistic regression. 
For purpose of logistic regression analysis, dummy variables were used for independent variables 
with more than two categories. Additionally, initial sputum smear and culture grading were 
dichotomized into ≤ 2+ or 3+. All binary categorical variables were coded as 0 and 1. Height, 
weight and arm circumference was grouped in equal categories based on sex-specific tertiles (at 
33.3 and 66.7 percentiles). The logistic regression analyses were adjusted for age and sex. Finally 
multivariate logistic regression analysis was undertaken by including factors found significant or 
marginally (P<0.10) significant in univariate logistic analysis, and adjusting for age, sex and HIV 
status irrespective of their association with the outcome. A P- value of 0.05 was set for statistical 
significance. 
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4.7. Definitions 
Sputum smear conversion; defined as the proportion of initial smear-positive patients with a 
negative smear at the end of 2 months of the intensive phase of anti-TB treatment (33).  
Sputum culture conversion; defined as the proportion of initial culture-positive patients with 
negative culture at the end of 2 months of intensive phase of anti-TB treatment (33).  
Background characteristic in this study include; age, sex, marital status, occupation, religion 
and smoking. 
Infectious background characteristics include; initial AFB smear grading, initial tubercle 
bacilli culture grading, BCG scar, CD4 count, haemoglobin and white blood cell count. 
Anthropometric background characteristics include; height, weight, body mass index, and arm 
circumference. 
Anaemia; defined as haemoglobin less than 120g/l for females and less than 130g/l for males. 
4.8. Ethical consideration 
 The study was conducted within the framework of the two ongoing randomised nutritional 
supplementation trials, which were granted permission from National ethics committee in 
Tanzania on 10th February 2006 (please see appendix for a copy). These studies, with registration 
number NCT00311298 follow guidelines for clinical trials. Oral and written information in 
Swahili was provided to all participants prior to obtaining informed oral and written consent. 
Guardian or parents were requested for consent for those who were under 18 years of age.
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5.0 RESULTS 
A total of 601 PTB positive patients were enrolled into this cohort from April 2006 to November 
2008, of which 249 (41%) were HIV+. Of these 601 patients, 516 (86%) patients showed up at the 
end of 2nd month of intensive phase treatment, and were included in the final analysis for 
calculation of conversion rates based on sputum smear examination. Of the 85 patients excluded 
from the study, 24 patients failed to come at the 2nd month visit, 11 patients died before 
completing the 2nd month visit, and 50 patients failed to provide sputum at the 2nd month visit. 
Among those recruited at baseline, only 447 (74.4%) patients were included in the final analysis 
for calculating the sputum culture conversion rate, as 26 (4.3%) patients were excluded after their 
culture results were found to be contaminated at baseline. An additional 21 (4.1%) patients were 
excluded after having contaminated culture results at the 2nd month of follow up and for 22 (3.7%) 
patients the baseline sputum cultures were negative. (Figure 3 and 4). 
5.1. Characteristics of sputum smear positive pulmonary TB patients recruited 
 For the patients recruited, the mean age was 35 years (range, 15 to 84 years) for HIV- patients 
and 34.5 years (range, 18 to 80) for the HIV+ patients (P=0.51). The proportion of females was 
higher among the HIV+ compared to HIV- patients (49% and 29% respectively, P<0.001). The 
proportion of patients who were separated, widowed or divorced was higher among HIV+ 
compared to HIV- (24.4% vs 15.1%, P=0.01). The proportion of patients who never smoked 
(72.3%) was higher among the HIV+ group compared to the HIV- group (61.7%) [P=0.001]. They 
were no difference observed between the HIV+ and HIV- groups with respect to occupation and 
religion (Table 1). 
5.2. Infectious and anthropometric background characteristics for patients recruited   
A higher proportion of HIV- patients had a baseline AFB smear grading of 3+ as compared to 
HIV+ patients (72.5 % HIV- and 55.8% HIV+, P<0.001). The mean CD4 count was 315 (95% CI 
287; 343) for HIV+ and 553 (95% CI 518; 588) for HIV- patients (P<0.0001). The proportion of 
patients with anaemia was higher among HIV+ patients as compared to the HIV- patients (96.8% 
vs. 85. 2% P, <0.001). As expected, patients who were HIV+ had a lower mean WBC (109cells/l) 
[6.6 (95%CI 6.3; 7.0)], weight (kg/m2) [50.3 (95%CI 49.2; 5I.4)], and arm circumference (cm) 
[22.3(95%CI 21.9; 22.7)] as compared with HIV- patients. 
 [WBC; 7.4(95%CI 7.2; 7.7)], [weight; 51.7 (95%CI 50.9; 52.6)], and [arm circumference; 22.9 
(95%CI 22.6; 23.2)] (Table 2).
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Figure 3. Flow chart for PTB+ patients followed for sputum smear conversion at the end of the 
2nd month of the intensive phase treatment. 
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Figure 4. Flow chart for PTB+ patients followed for sputum culture conversion at the end of the 
2nd month of the intensive phase treatment. 
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5.3 Sputum smear conversion at the end of two month of intensive phase 
Sputum smear conversion among the 516 PTB positive patients was observed in 394 (76.4%) 
patients. Fifteen percent females and 28.9% males (P<0.001) remained sputum smear positive at 
the end of the 2nd months of anti-TB treatment. There was no difference observed in sputum smear 
conversion among PTB positive patients as categorised by age, occupation and smoking (Table 
3.). Patients with an initial pre-treatment AFB smear grading of 3+ had a lower conversion rate 
(72.1%) compared to patients with other sputum smear grading categories (P=0.004). Among 
patients with a BCG scar, 78.9% achieved sputum smear conversion as compared to 66% in 
patients who did not have a BCG scar (P=0.006) (Table 4). Of those patients with a body weight 
of ≥18.5kg/m2, 15.3% did not sputum smear convert at the end of the 2nd month of anti-TB 
treatment as compared to 30.3% who had a weight of ≥17- <18.5 kg/m2 and 29.2% with weight 
<17 kg/m2 [P=0.001]. Patients with an arm circumference in the lower tertile were observed to 
have a lower sputum smear conversion rate as compared to those in middle and upper tertiles 
(69.5%, 78.9%, 80.3%, respectively P=0.04). There was no difference observed between sputum 
smear conversion rates among the PTB patients as categorised by HIV status, anaemia, CD4 
count, WBC counts and height (Table 4). 
5.4. Sputum culture conversion at the end of two month of intensive phase  
Of the 447 patients analysed based on sputum culture, 26 patients (5.8%) remained sputum culture 
positive at the end of the 2nd month of the intensive phase. There was no observed difference 
between sputum culture conversion among patients as categorised by age, sex, marital status, 
occupation, smoking and religion (Table 5). However, a higher proportion of patients who had a 
pre-treatment AFB grading of 3+ failed to convert as compared to patients with a baseline sputum 
grading of ≤2+ (7.3% and 1.0%, respectively P=0.016). Thirteen percent of those who did not 
have a BCG scar did not sputum culture convert as compared to 4.2% of those who had a BCG 
scar (P=0.002). No significant difference was observed in sputum culture conversion among PTB 
patients as categorised by HIV status, CD4 count, WBC count, Hb levels and BMI (Table 6). 
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5.5. Factors associated with sputum smear and culture conversion 
Logistic regression was performed to identify factors that were independently associated with 
persistence of sputum smear and culture positivity at the end of the 2nd month post anti-TB 
treatment as categorised by background, infectious and anthropometric factors. Thus, being of 
male sex (OR 2.11, [95%CI 1.31 ; 3.40] P=0.002), an initial AFB smear grading of 3+ (OR 2.24, 
[95%CI 1.38 ; 3.65], P=0.001), presence of a BCG scar (OR 0.54, [95%CI 0.33 ; 0.88], P=0.015), 
having a BMI of ≥17- <18.5 kg/m2 (OR 2.30, [95%CI 1.33 ; 3.99], P=0.003), and BMI of <17 
kg/m2 (OR 2.42, [95%CI 1.46 ; 4.02], P=0.001) were significantly related to persistence of 
sputum smear positivity at the 2nd month following anti-TB treatment (Table 7). Regarding 
factors associated with persistence of sputum culture positivity, the presence of a BCG scar (OR 
0.27, [95%CI 0.11; 0.62], P=0.002) remained significant (Table 8). 
 In the multivariate regression model, factors that remained independently associated with 
persistent sputum smear positivity included:- male gender (OR 1.92, [95% CI 1.16; 3.18], 
P=0.01), an initial AFB smear grading of 3+ (OR 1.9, [95% CI 1.17; 3.19] P=0.01), having a BMI 
of <17 kg/m2 (OR 2.18, [95%CI 1.31; 3.64], P=0.01), and BMI of ≥17- <18.5 kg/m2 (OR 2.17, 
[95%CI 1.24; 3.79], P=0.006) (Table 9). There was a 43% (OR 0.57, [95%CI 0.35; 0.95], 
p=0.032) and 72% (OR 0.28, [95%CI 0.11; 0.62], P =0.002) lower probability of not sputum 
smear converting and culture converting respectively, at the end of the 2nd month of intensive 
phase therapy if the patients had a BCG scar (Table 9).
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6.0 DISCUSSION 
6.1. Methodological issues. 
6.1.1. Validity 
The extent to which study cofounders are successfully eliminated and independent variables 
produce an observed effect are measures of internal validity, while if the study findings can be 
generalised to a wider population the study is said to have a high external validity (34). 
6.1.2. Internal validity 
In our study the following factors might have affected the validity of our findings: 
 6.1.2.1. Instrumentation bias 
Digital weighing scales, partec cyflow CD4 count machine, measuring boards, tape measures and 
microscopy were used in this study. Reliability of the readings provided by these instruments is 
dependent upon continuous calibration as well as the proficiency of an observer. Error was 
minimised by providing regular training to the study team on use of instruments. Furthermore 
instruments were calibrated at regular intervals to ensure consistency in results. 
6.1.2.2. Recalling bias 
There is a possibility that patients do not recall past history and/or may not provide an accurate 
history of smoking. However, this bias should be taken care of by the randomization undertaken 
for the ongoing nutritional intervention trials from where the patients for the present study were 
recruited. 
6.1.2.3. Confounding factors  
Age and gender influences the chance of being exposed to infections as well as the risk of 
developing primary disease (35, 36). Age has been shown to have an impact on sputum 
conversion (25, 37). Factors such as age and gender may act as confounders and bias our 
outcomes. In our study, biases that may have risen due to these factors were controlled in a 
logistic analysis.  
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6.2.3. External validity 
Our study was undertaken in the northern part of Tanzania. Northern Tanzania has a mixture of 
different tribes from almost all parts of country. Despite limiting ourselves in recruiting only 
patients residing in the study area, our results on the influence of age, gender, and initial sputum 
smear grading and BMI on sputum smear conversion do not differ significantly from those 
reported in similar studies conducted elsewhere (26-28). 
 
6.2 Discussion based on results 
The overall sputum smear conversion rate was 76.4% and the sputum culture conversion rate was 
94.2%. Twenty seven percent of patients who were HIV- and 18.5 % of patients who were HIV+ 
did not convert by sputum smear examination while 6.6% of HIV- and 4.6% of HIV+ patients did 
not convert at the end of the 2nd month of intensive phase as examined by sputum culture. The 
high conversion rates observed is a reflection of the success of the NTLP in the overall control of 
TB in the area where this study was undertaken. Drug susceptibility testing of the 26 isolates from 
the patients who did not convert based on sputum culture examination has not been performed as 
yet. A recent study from Tanzania on drug susceptibility testing of 111 M.tb isolates from PTB 
patients indicate that 10.8% of the isolates were resistant to at least one anti-TB drugs and 2.7% 
were resistant to isoniazid and rifampicin ( multi-drug resistant TB) (38). A higher conversion rate 
observed by sputum culture examination as compared with sputum smear examination may not be 
surprising. Sputum culture examination has a higher sensitivity and specificity as compared to 
sputum smear examination (9). Moreover, sputum samples contain dying or dead AFB that may 
contribute to positive sputum microscopic results but such samples are negative on sputum culture 
examination.  
 Our study shows that the sputum conversion rate observed varied among the different patient 
categories. PTB patients with pre-treatment initial AFB smear grading of 3+ had a significantly 
lower sputum smear and culture conversion rate (for smear 72.1% and for culture 93.1%) as 
compared with patients with an initial AFB smear grading of 1+ or ≤ 2+ (for smear 82.4% and for 
culture 96.5%). These results concur with findings from other studies undertaken in for e.g. India, 
Thailand and Gambia (26-28). As AFB multiply in the lung, there is an increase in the cavitating 
lesions that appear in the lung (39). Bacillus load correlates with an increase in consolidation 
which usually manifests as an exudative or caseous necrosis (39). The initial action of anti-TB 
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drugs is to decrease the numbers of bacilli in lung lesions resulting in improvement of lung 
consolidation. Thus, patients with an initial low mycobacteriological load (low AFB grading) tend 
to convert earlier (39).   
Our study shows that there was no significant difference in conversion rates among TB patients 
co-infected and those not infected with HIV. Neither sputum smear microscopy (72.9%, HIV- vs. 
81.5% HIV+) nor sputum culture (93.4%, HIV- vs. 95.4%, HIV+) conversion rates were 
significantly different for PTB patients with or without HIV co-infection. These findings are in 
contrast with a similar study undertaken in North Carolina, USA where it was reported that TB 
patients co-infected with HIV have a lower rate of sputum conversion than did PTB patients 
without HIV (for HIV- 73.6% and for HIV+ 57.8%) (11). A study undertaken in Uganda on 
tuberculosis chemotherapy and sputum smear conversion among HIV- and HIV+ PTB patients, 
found no significant difference in conversion among HIV+ and HIV- patients (13). Previous 
studies have documented that HIV+ PTB patients have fewer cavitating lung lesions than do HIV- 
PTB patients (40). Thus anti-TB drugs would presumably clear bacilli equally effectively in HIV+ 
patients as well as in HIV- PTB patients. To maintain these high conversion rates DOT providers 
and clinicians should continue to emphasise a strict adherence to anti-TB drugs in both HIV+ and 
HIV- PTB patients. 
CD4+ counts despite playing a role in immunity did not significantly influence the sputum 
conversion rate. This study shows no difference in sputum conversion rates with different CD4+ 
counts. Patients with CD4+ counts of ≤ 200, 201-350 and >350 had sputum smear conversion 
rates of 81.3%, 75.8% and 74.6%, respectively and sputum culture conversion rate of 97.8%, 
91.6% and 93.9 respectively. Similar results were observed in a study by Singla et al in Saudi 
Arabia (24), and by Domínguez- Castelleno et al in Spain (29), who showed no relation between 
CD4+ counts and sputum conversion rates. Furthermore, in concordance with other studies (25), 
we show that the Hb level and total WBC counts did not seem to influence the sputum conversion 
rate. 
Interaction between malnutrition and TB is associated with complex mechanisms (41). TB disease 
has an effect on the nutritional status by affecting dietary intake due to loss of appetite, poor 
absorption of nutrients from the intestine and increase uptake of nutrients by specific target tissue 
due to increase of body metabolism (17). Both micro and macro nutrient deficiency can influence 
susceptibility to TB. Severe malnutrition has a profound effect on cell-mediated immunity (41). 
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BMI is one of indicators of nutritional status and was below 18.5 kg/m2 in majority of the TB 
patients in our study at the time of TB diagnosis. A study conducted in Tanzania on nutritional 
status and weight gain in patients with pulmonary TB showed 77% of males and 58% of females 
had a BMI below 18.5kg/m2 at the time of admission (41). Furthermore, a study from Malawi, 
showed that there was a reduction of 20% in BMI (from 21.7 to 17.3) among PTB patients as 
compared with matched controls (15). In this study, the mean BMI among PTB patients with HIV 
and those without HIV was 18.4 and 18.3, respectively, at the time of recruitment. The sputum 
smear conversion rate was 69.7% for patients with BMI <18.5kg/m2 and 84.7% for BMI 
≥18.5kg/m2 while the culture conversion rate was 90.3% for BMI <18.5 kg/m2 and 95% for ≥ 18.5 
kg/m2 at the end of the 2nd month of intensive phase. Thus, PTB patients who are malnourished 
are at a risk of sputum smear persistence at the end of 2nd month post anti-TB treatment.   
Multivariate analysis was performed to document those variables independently associated with 
sputum smear and culture conversion at the end of the 2nd month following anti-TB treatment. The 
factors that showed a statistically significant and independent relationship with sputum smear 
conversion were; initial (pre-treatment) smear grading, male gender, BMI, and the presence of a 
BCG scar. The presence of a BCG scar was also positively associated with sputum culture 
conversion at the end of the 2nd month of the intensive phase of anti-TB treatment.  
Association with initial smear grading, male gender and BMI on sputum conversion has also 
reported on previous studies. (23-25, 27, 40). Patients with numerous AFB in the sputum reflect 
the high numbers of bacilli in the lung, with a corresponding increase in cavity formation. Thus, a 
delayed sputum conversion in patients with high initial bacillary loads in the sputum is not 
surprising (39, 40). Male gender was reported by Banu Rekha et and  Güler et al as an 
independent factor associated with sputum conversion (23, 25). Males are generally more likely to 
be smokers and to consume alcohol. Smoking and alcohol have been observed to be associated 
with a delay in seeking health care as well as contributing to a poor compliance to anti-TB 
medication. Thus, these factors may contribute to a delayed sputum conversion (42, 43). 
 The BCG vaccine is still the only vaccine in use against TB, although recently efforts to develop 
new vaccines are in progress (44). Globally, the BCG vaccine is delivered to approximately 90% 
of all infants (44). Meta analysis of BCG trials has reported the protective efficacy of the vaccine 
to vary across populations and range from 0% to 86% (45, 46). The protective effect against 
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severe forms of meningeal and miliary TB was 79% (46). The risk of acquiring TB was reduced 
by 50% in vaccinated individuals (45). Meta analysis of BCG trials data also suggested that the 
protective efficacy of BCG may persist 10 years or more after infant vaccination (47). A recent 
study  by Weir et al showed that BCG vaccination during infancy and adolescence can induce 
immunological memory to mycobacterial antigens that is measurable up to 14 years (48). 
Additionally, a study looking at long term BCG efficacy among American Indians and Alaska 
natives, showed that protection could last up to 60 years (49). The BCG vaccine is given to all 
infants in Tanzania at birth and is included in the expanded programme of immunization (EPI). 
Factors like differences in exposure to different strains of M.tb as well as to atypical mycobacteria 
from one geographical area to another, different BCG vaccines strains used, genetic characteristics 
of the population, and nutritional differences among different populations could contribute to the 
variable efficacy of BCG(50). 
In this study interestingly, the presence of a BCG scar was significantly associated with sputum 
smear and culture conversion. Thus, patients with a BCG scar were 43% less likely by sputum 
smear microscopy and 72% less likely by sputum culture to remain positive at the end of 2nd 
month of intensive phase of anti-TB treatment. This exciting finding needs to be confirmed in 
larger studies in Tanzania as well as in other geographical locations and populations.
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7.0 CONCLUSIONS  
We show that initial (pre-treatment) high smear grading, male gender, low BMI, and the absence 
of a BCG scar are associated with persistent sputum smear positivity (at the end of the intensive 
phase of anti-TB treatment). The absence of a BCG scar was also positively associated with 
persistent sputum culture positivity. HIV status, CD4 counts and Hb levels were not associated 
with delayed sputum conversion.  
1. The presence of a BCG scar should be documented and included in models predicting  
sputum conversion. 
2.  Clinicians should carefully assess PTB patients who are at risk of not converting using  
identified predicting factors.  
3. Emphasis on nutritional health education, promotion and support should be considered for  
all TB patients regardless of HIV status.  
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Table 1. Background characteristics for 601 sputum positive pulmonary TB patients categorised by HIV status 1 
 HIV status  
 
 
Total 
n 
Negative 
n=352 
Positive 
n=249 
P value2 
Age (years) 601 35.0 (15-84)   34.5 (18-80) 0.51 
Sex 
  Female 
  Male 
601  
102 (29.0) 
250 (71.0) 
 
122 (49.0) 
127 (51.0) 
 
   <0.001 
Marital status 
  Married or cohabiting 
  Single 
  Separated, widowed or divorced 
598  
199 (56.5) 
100 (28.4) 
53 (15.1) 
 
    122 (49.6) 
  64 (26.0) 
  60 (24.4) 
 
0.01 
Occupation 
  Farmer 
  Businessman 
  Other 
600  
135 (38.4) 
79 (22.4) 
138 (39.2) 
 
81 (32.7) 
63 (25.4) 
   104 (41.9) 
 
0.35 
Religion 
  Christian 
  Muslim 
  Other 
601  
257 (73) 
78 (22.2) 
17 (4.8) 
 
    191 (76.7) 
      54 (21.7) 
    4   (1.6) 
 
0.09 
Smoking 
  Current smoker 
  Past smoker 
  Never smoker 
601  
86 (24.4) 
49 (13.9) 
217 (61.7) 
 
     27 (10.8) 
     42 (16.9) 
   180 (72.3) 
 
0.001 
1 Data are provided as mean (range) for age or n (%). 
2
 X2 – test used for categorical variables and the t- test for continuous variables.  
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Table 2. Infectious and anthropometric background characteristics for 601 pulmonary TB categorised by 
HIV status1 
  
HIV status 
 
 Total 
n 
Negative 
n=352 
Positive 
n=249 
P value2 
Initial AFB smear grading3 
  ≤1+ 
    2+ 
    3+ 
601  
43 (12.2) 
54 (15.3) 
255 (72.5) 
 
57 (22.9) 
53 (21.3) 
139 (55.8) 
 
<0.001 
Initial AFB culture grading4 
    1+ 
    2+ 
    3+ 
546  
24 (7.6) 
44 (13.8) 
250 (78.6) 
  
26 (11.4) 
39 (17.1) 
             163 (71.5) 
 
0.14 
BCG scar 
 
 No 
  Yes 
600  
71 (20.2) 
281 (79.8) 
 
                47 (19.0) 
              201 (81.0) 
 
0.71 
CD4 count (106 cells/ml) 600 553 (518 ; 588)       315 (287 ; 343) <0.0001 
Haemoglobin  
  Non anaemic 
  Anaemic  
600  
52 (14.8) 
300 (85.2) 
 
     8 (3.2) 
              240 (96.8) 
 
<0.001 
WBC (x109cells/l) 600 7.4 (7.2 ; 7.7)              6.6 (6.3 ; 7.0) 0.0003 
Height (cm) 599 167.8 (166.9 ; 168.7) 165.6 (164 ; 166.6) 0.0009 
Weight (kg) 600 51.7 (50.9 ; 52.6) 50.3 (49.2 ; 51.4) 0.03 
BMI (kg/m2 )  599 18.4 (18.1 ; 18.6) 18.3 (18.0 ; 18.7) 0.92 
Arm circumference (cm) 601 22.9 (22.6 ; 23.2) 22.3 (21.9 ; 22.7) 0.03 
1 Data are mean (95% confidence interval) or n (%).  
2
 X2 – test used for categorical variables and the t- test for continuous variables. 
3Smear grading by auramine microscopy defined as ≤1+ if is 1-99 AFB per 100 fields; 2+ = 1-10 AFB per field;     
  3+ = more than 10 AFB per field.   
4
 Culture grading defined as 1+ = 1-100 colonies; 2+ = more than 100 colonies and 3+ = confluent growth colonies. 
  BMI= body mass index; AFB= acid fast bacilli; WBC= White blood cell count; BCG =Bacilli Calmette-Guérin. 
  Anaemia defined as haemoglobin less than 120g/l for females and less than130g/l for males. 
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Table 3. Sputum smear conversion among 516 pulmonary TB patients at the end of the 2nd month of   
                intensive phase categorised by background characteristics 1 
 
 Smear results 
 
 
Total 
n 
Converted 
n=394 
Not converted 
n=122 
P value2 
Age (years) 
 15-24  
  25-34  
  35-44  
  ≥45 
516  
 71 (78.0) 
         157 (80.9) 
 99 (75.0) 
67 (67.7) 
 
20 (22.0) 
37 (19.1) 
33 (25.0) 
32 (32.3) 
 
0.08 
Sex 
  Female 
  Male 
516  
165 (85.0) 
229 (71.1) 
 
29 (15.0) 
93 (28.9) 
 
  <0.001 
Marital status 
  Married or cohabiting 
  Single 
  Separated, widowed or divorced 
516  
217 (78.1) 
109 (77.3) 
  68 (70.1) 
 
 61 (21.9) 
 32 (22.7) 
        29 (29.9) 
 
0.27 
Occupation 
  Farmer 
  Businessman 
  Other 
515  
134 (74.0) 
105 (84.0) 
154 (73.7) 
 
47 (26.0) 
20 (16.0) 
55 (26.3) 
 
0.07 
Religion 
  Christian 
  Muslim 
  Other 
516  
296 (77.3) 
  90 (75.0) 
   8 (61.5) 
 
87 (22.7) 
30 (25.0) 
  5 (38.5) 
 
0.39 
Smoking 
  Current smoker 
  Past smoker 
  Never smoker 
516  
69 (70.4) 
55 (70.5) 
     270 (79.4) 
 
29 (29.6) 
23 (29.5) 
        70 (20.6) 
 
0.08 
1 Data are n (%).  
2
 X2 – test for categorical variables. 
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Table 4. Sputum smear conversion among 516 pulmonary TB patients at the end of the 2nd 
              month of intensive phase categorised by infectious and anthropometric characteristics1 
 
Total 
    n 
Converted 
n=394 
Not converted 
n=122 
P value2 
Initial AFB smear grading3 
  ≤1+ 
    2+ 
    3+ 
516   
70 (82.4) 
 76 (87.4) 
       248 (72.1) 
   
  15 (17.6) 
   11 (12.6) 
   96 (27.9) 
 
0.004 
Initial AFB culture grading4 
    1+ 
    2+ 
    3+ 
468  
34 (79.0) 
49 (71.0) 
       276 (76.9) 
  
   6 (21.0) 
  20 (29.0) 
         83 (23.1) 
 
  0.25 
BCG scar 
  No 
  Yes 
515  
  68 (66.0) 
       325 (78.9) 
 
         35 (34.0) 
         87 (21.1) 
 
0.006 
HIV 
  Negative 
  Positive 
516  
226 (72.9) 
168 (81.5) 
 
          84 (27.1) 
          38 (18.5) 
 
  0.16 
Haemoglobin level  
  Non anaemic 
  Anaemic  
516  
45 (83.3) 
      349 (75.5)  
 
            9 (16.7)  
        113 (24.5)  
 
  0.20 
CD4 count (106cells/ml)  
  ≤200       
  201-350  
  >350       
516  
91 (81.3) 
97 (75.8) 
      206 (74.6) 
 
 21 (18.7) 
 31 (24.2) 
         70 (25.4) 
 
 0.38 
WBC (109 cells/l) 
  <4.0 
  4.0-11.0 
  >11.0 
   516  
        46 (82.1) 
      331 (76.1) 
        17 (68.0) 
 
10 (17.9) 
      104 (23.9)       
  8 (32.0) 
 
0.36 
Height5 
  Lower tertile 
  Middle tertile 
  Upper tertile 
516  
130(76.5) 
138 (79.8) 
126 (72.8) 
 
40 (23.5) 
35 (20.2) 
        47 (27.2) 
 
0.32 
Weight5 
  Lower tertile 
  Middle tertile 
  Upper tertile 
516    
        129 (73.7) 
        120 (71.9) 
        145 (83.3) 
 
46 (26.3) 
47 (28.1) 
29 (16.7) 
 
0.03 
BMI (kg/m2 )  
  <17 
  ≥17- <18.5 
  ≥18.5 
516  
        126 (70.8) 
   85 (69.7) 
        183 (84.7) 
 
        52 (29.2) 
37 (30.3) 
33 (15.3) 
 
0.001 
Arm circumference5 
  Lower tertile 
  Middle tertile 
  Upper tertile 
516  
116 (69.5) 
127 (78.9) 
151 (80.3) 
 
51 (30.5) 
34 (21.1) 
        37 (19.7) 
 
 0.04 
1 Data are n (%):  2 X2 – test for categorical variable.  
3By auramine microscopy defined as ≤1+ = 1-99 AFB per 100 fields; 2+ = 1-10 AFB per fields; 3+ = more than 10    
  AFB per field.  
4
 1+ = 1-100 colonies; 2+ = more than 100 colonies and 3+ = confluent colonies.  
5Height, weight and arm circumference divided to 33.3 and 66.7 percentile and based on sex specific tertiles.  
Lower tertile cut off; height <158.2 for females and <167.1 for males, weight <43.1 for females and <49.7 for males, 
arm circumference <20.6 for females and <21.1 for males.  
Middle tertile cut off; height 158.2-164.2 for females and 167.1-173 for males, weight 43.1-50 for females and 49.7- 
55.3 for males, arm circumference 20.6-23 for female and 21.1- 23.4 for males. 
 Upper tertile cut off; height ≥164.3 for females and ≥ 173.1 for males, weight ≥ 51 for females and ≥ 55.4 for males, 
arm circumference ≥ 24 for females and ≥23.5 for males. BMI= body mass index; BMI graded according to WHO 
recommendations.  
Anaemia defined as haemoglobin less than 120g/l for females and less than130g/l for males. 
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Table 5. Sputum culture conversion among 447 pulmonary TB patients at the end of the 2nd month of the 
                intensive phase categorised by background characteristics1 
  Culture  results  
 Total 
n 
Converted 
n=421 
Not converted 
n=26 
P value2 
Age (years) 
  15-24  
  25-34  
  35-44  
  ≥45 
447  
  72 (90.0) 
170 (96.1) 
100 (92.6) 
  79 (96.3) 
 
8 (10.0) 
  7 (3.9) 
8 (7.41) 
3 (3.67) 
 
0.18 
Sex 
  Female 
  Male 
447  
158 (96.3) 
263 (92.9) 
 
 6 (3.7) 
20 (7.1) 
 
0.14 
Marital status 
  Married or cohabiting 
  Single 
  Separated, widowed or divorced 
447  
235 (95.9) 
115 (91.3) 
  71 (93.4) 
 
10 (4.1) 
11 (8.7) 
  5 (6.6) 
 
0.18 
Occupation 
  Farmer 
  Businessman 
  Other 
446  
139 (93.3) 
112 (94.9) 
169 (94.4) 
 
10 (6.7) 
  6 (5.1) 
10 (5.6) 
 
0.84 
 
Religion 
  Christian 
  Muslim 
  Other 
447  
308 (94.5) 
104 (94.6) 
    9 (81.8) 
 
18 (5.5) 
  6 (5.4) 
 2 (18.2) 
 
0.21 
Smoking 
  Current smoker 
  Past smoker 
  Never smoker 
447  
80 (90.9) 
64 (94.1) 
    277 (95.2) 
 
 8 (9.1) 
 4 (5.9) 
14 (4.8) 
 
0.32 
1 Data are n (%). 
2
 X2 – test used for categorical variables. 
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Table 6. Sputum culture conversion among 447 pulmonary TB patients at the end of the 2nd 
               month of the intensive phase categorised by infectious and anthropometric characteristics1 
 
Total 
n 
Converted 
n=421 
Not converted 
n=26 
P value2 
Initial AFB smear grading3 
  ≤2+ 
    3+ 
447  
139 (96.5) 
282 (93.1) 
 
  5 (3.5) 
21 (6.9) 
 
0.14 
Initial AFB culture grading4 
  ≤2+ 
    3+ 
446  
102 (99.0) 
318 (92.7) 
 
  1 (1.0) 
25 (7.3) 
 
0.02 
BCG scar 
  No 
  Yes 
446  
 74 (87.0) 
346 (95.8) 
 
11 (13.0) 
  15 (4.2) 
 
0.002 
HIV 
  Negative 
  Positive 
447  
255 (93.4) 
166 (95.4) 
 
18 (6.6) 
  8 (4.6) 
 
0.38 
Haemoglobin level  
   Non anaemic  
   Anaemic 
447  
43 (93.5) 
            378 (94.3) 
 
  3 (6.5) 
23 (5.7) 
 
0.83 
CD4 count (106cells/ml)  
  ≤200       
  201-350  
  >350       
447  
  90 (97.8) 
  98 (91.6) 
233 (93.9) 
 
  2 (2.2) 
  9 (8.4) 
15 (6.1) 
 
0.17 
WBC (109 cells/l) 
  <4.0 
  4.0-11.0 
  >11.0 
447  
  45 (97.8) 
356 (93.7) 
  20 (95.2) 
 
 1 (2.2) 
24 (6.3) 
  1 (4.8) 
 
0.51 
Height5 
  Lower tertile 
  Middle tertile 
  Upper tertile 
447  
139 (95.2) 
143 (96.0) 
139 (91.4) 
 
7 (4.8) 
6 (4.0) 
13 (8.6) 
 
0.20 
Weight5 
  Lower tertile 
  Middle tertile 
  Upper tertile 
447  
144 (93.5) 
130 (95.6) 
147 (93.6) 
 
10 (6.5) 
  6 (4.4) 
10 (6.4) 
 
0.70 
BMI (kg/m2 )  
  < 17 
  ≥17- <18.5 
  ≥18.5 
447  
149 (94.9) 
 93 (90.3) 
179 (95.7) 
 
 8 (5.1) 
10 (9.7) 
  8 (5.3) 
 
0.15 
Arm circumference5 
  Lower tertile 
  Middle tertile 
  Upper tertile 
447  
132 (93.6) 
127 (93.4) 
162 (95.3) 
 
9 (6.4) 
9 (6.6) 
8 (4.7) 
 
0.73 
1 Data are n (%). 
 
2
 X2 – test used for categorical variable.  
3
 By auramine microscopy defined as ≤2+ = 1-99 AFB per 100 fields or 1-10 AFB per field; 3+ = more than 10 
AFB per field. 
 
4
 Culture grading defined as ≤2+ = more than 1 colony; 3+ = confluent colonies.  
5Height, weight and arm circumference divided to 33.3 and 66.7 percentile and based on sex specific tertiles.   
Lower tertile cut off; height <158.2 for females and <167.1 for males, weight <43.1 for females and <49.7 for 
males, arm circumference <20.6 for females and <21.1 for males.  
Middle tertile cut off; height 158.2-164.2 for females and 167.1-173 for males, weight 43.1-50 for females and 
49.7- 55.3 for males, arm circumference 20.6-23 for females and 21.1- 23.4 for males. 
 Upper tertile cut off; height ≥164.3 for females and ≥173.1 for males, weight ≥51 for females and ≥55.4 for 
males, arm circumference ≥24 for females and   ≥23.5 for males.  BMI graded according to WHO 
recommendations.  
Anaemia defined as Hb <120g/l for females and <130g/l for males. 
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Table 7. Analysis of factors associated with persistent sputum smear positivity at the end of the 2nd month  
               of  intensive phase 
  
Converted 
Not 
converted 
 
Crude 
 
Adjusted1 
  
n 
 
n 
 
OR (95% CI) 
 
OR (95%CI) 
P 
value 
Age (years)2 
  15-24  
  25-34  
  35-44  
  ≥45  
 
71 
157 
99 
67 
 
20 
37 
33 
32 
 
1.19 (0.64 ; 2.20) 
1.0 
1.12 (0.93 ; 1.34) 
1.19 (1.03 ; 1.37) 
 
1.16 (0.62 ; 2.16) 
1.0 
1.09 (0.90 ; 1.30) 
1.13 (0.98 ; 1.30) 
 
0.63 
 
0.36 
0.09 
Sex2 
 Female 
 Male 
 
165 
229 
 
29 
93 
 
1.0 
2.31 (1.45 ; 3.66) 
 
1.0 
2.11 (1.31 ; 3.40) 
 
 
0.002 
Religion 
  Christian  
  Muslim  
  Other  
 
296 
90 
8 
 
87 
30 
5 
 
1.0 
1.13 (0.70 ; 1.82) 
1.46 (0.82 ; 2.58) 
 
1.0 
1.14 (0.70 ; 1.86) 
1.30 (0.72 ; 2.34) 
 
 
0.58 
0.38 
Marital status 
  Married or cohabiting 
  Single  
  Separated, divorced & widowed 
 
217 
109 
68 
 
61 
32 
29 
 
1.0 
1.04 (0.64 ; 1.69) 
1.52 (0.90 ; 2.54) 
 
1.0 
1.2 (0.68 ; 2.08) 
1.7 (1.00 ; 3.04) 
 
 
0.54 
0.049 
Occupation 
  Farmer  
  Businessman  
  Other 
 
134 
105 
154 
 
47 
20 
55 
 
1.0 
0.54 (0.30 ; 0.97) 
1.01 (0.65 ; 1.60) 
 
1.0 
0.57 (0.31 ; 1.05) 
1.10 (0.69 ; 1.76) 
 
 
0.07 
0.68 
Smoking  
 Current smoker  
 Past smoker  
 Never smoker  
 
69 
55 
270 
 
29 
23 
70 
 
1.62 (0.97 ; 2.69) 
1.61 (0.92 ; 2.80) 
1.0 
 
1.10 (0.62 ; 1.92) 
1.13 (0.62 ; 2.06) 
1.0 
 
0.74 
0.68 
Initial AFB smear grading3 
    ≤2+  
      3+ 
 
146 
248 
 
26 
96 
 
1.0 
2.2 (1.35 ; 3.51) 
 
1.0 
2.24 (1.38 ; 3.65) 
 
 
0.001 
Initial AFB culture grading4 
    ≤2+  
      3+ 
 
83 
276 
 
26 
83 
 
1.0 
0.96 (0.58 ; 1.59) 
 
1.0 
0.93 (0.56 ; 1.57) 
 
 
0.79 
BCG scar 
  No 
  Yes 
 
68 
325 
 
35 
87 
 
1.0 
0.52 (0.32 ; 0.83) 
 
1.0 
0.54 (0.33 ; 0.88) 
 
 
0.02 
HIV status 
  Negative 
  Positive 
 
226 
168 
 
84 
38 
 
1.0 
0.60 (0.39 ; 0.93) 
 
1.0 
0.70 (0.44 ; 1.10) 
 
 
0.12 
Haemoglobin  
  Non anaemic   
  Anaemic  
 
45 
349 
 
9 
113 
 
1.0 
0.61 (0.78 ; 3.42) 
 
1.0 
1.78 (0.83 ; 3.79) 
 
 
0.14 
36 
 
 
 
                                                                                                                                                                                                         
Table 7-continued
  
converted 
Not 
converted 
 
Crude 
 
Adjusted1 
  
n 
 
n 
 
OR (95% CI) 
 
OR (95%CI) 
P 
value 
White blood cell count (109cells/l) 
  <4.0  
  4.0 -11.0  
  >11.0  
 
46 
331 
17 
 
10 
104 
8 
 
0.69 (0.33 ; 1.410 
1.0 
1.14 (0.85 ; 1.52) 
 
0.75 (0.36 ; 1.55) 
1.0 
1.12 (0.83 ; 1.51) 
 
0.44 
 
0.43 
CD4 count (106cells/ml) 
  ≤200       
  201-350  
  >350       
 
91 
97 
206 
 
21 
31 
70 
 
0.68 (0.39 ; 1.17) 
0.94 (0.58 ; 1.53) 
1.0 
 
0.79 (0.44 ; 1.40) 
0.98 (0.59 ; 1.61) 
1.0 
 
0.43 
0.93 
Height5 
  Lower tertile 
  Middle tertile 
  Upper tertile 
 
130 
138 
126 
 
40 
35 
47 
 
1.21 (0.7 ; 2.02) 
1.0 
1.47 (0.89 ; 2.42) 
 
1.22 (0.71; 2.06) 
1.0 
1.56 (0.93 ; 2.60) 
 
0.47 
 
0.09 
Weight5 
  Lower tertile 
  Middle tertile 
  Upper tertile 
 
129 
120 
145 
 
46 
47 
29 
 
1.78 (1.06 ; 3.00) 
1.96 (1.16 ; 3.30) 
1.0 
 
1.72 (1.01 ; 2.93) 
1.98 (1.16 ; 3.36) 
1.0 
 
0.045 
0.01 
 
BMI (kg/m2 )  
   <17 
  ≥17- <18.5 
  ≥18.5 
 
126 
85 
183 
 
52 
37 
33 
 
2.29 (1.39 ; 3.74) 
2.41 (1.41 ; 4.12) 
1.0 
 
2.42 (1.46 ; 4.02) 
2.30 (1.33 ; 3.99) 
1.0 
 
0.001 
0.003 
 
Arm circumference 5 
  Lower tertile 
  Middle tertile 
  Upper tertile 
 
116 
127 
151 
 
51 
34 
37 
 
1.66 (0.93 ; 2.94) 
1.04 (0.57 ; 1.92) 
1.0 
 
1.61 (0.91 ; 2.88) 
1.01 (0.55 ; 1.88) 
1.0 
 
0.10 
0.95 
 
1OR adjusted for age and sex. 
2OR for effect of age adjusted for sex and OR for effect of sex adjusted for age.  
3Smear grading by auramine microscopy defined as ≤2+ = 1-99 AFB per 100 fields or 1-10 AFB per field; 3+ = more  
  than 10 AFB per field. 
4Culture grading defined as ≤2+ = more than 1colonies; 3+ = confluent colonies. 
5Height, weight and arm circumference divided to 33.3 and 66.7 percentile and based on sex specific tertiles. 
  Lower tertile cut off ; height <158.2 for females and <167.1 for males, weight <43.1 for females and <49.7 for   
  males, arm circumference <20.6 for female and <21.1 for males. 
  Middle tertile cut off; height 158.2-164.2 for females and 167.1-173 for males, weight 43.1-50 for females  
  and 49.7- 55.3 for males , arm circumference 20.6-23 for females and 21.1- 23.4 for males. 
  Upper tertile cut off; height ≥164.3 for females and ≥173.1 for males, weight ≥ 51 for females and ≥ 55.4 for males,  
  arm circumference ≥24 for females and ≥ 23.5 for  males. 
  OR= odd ratio; BMI= Body mass index; 95% CI= 95% confidence interval. 
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Table 8. Analysis of factors associated with persistent sputum culture positivity at the end of the 2nd   
               month of intensive phase 
  
Converted 
Not 
converted 
 
Crude 
 
Adjusted1 
  
n 
 
n 
 
OR (95% CI) 
 
OR (95%CI) 
P 
value 
Age (years)2 
  15-24  
  25-34  
  35-44  
  ≥45  
 
72 
170 
100 
79 
 
8 
7 
8 
3 
 
2.7 (0.94 ; 7.72) 
1.0 
1.94 (0.68 ; 5.52) 
0.92 (0.23 ; 3.66) 
 
2.61 (0.91 ; 7.51) 
1.0 
1.8 (0.62 ; 5.06) 
0.75 (0.19 ; 3.05) 
 
0.08 
 
0.29 
0.69 
Sex2 
 Female 
 Male 
 
158 
263 
 
6 
20 
 
1.0 
2.00 (0.79 ; 5.09) 
 
1.0 
2.1 (0.82 ; 5.45) 
 
 
0.12 
Religion 
  Christian  
  Muslim  
  Other  
 
308 
104 
9 
 
18 
6 
2 
 
1.0 
0.98 (0.38 ; 2.55) 
3.80 (0.76 ; 18.91) 
 
1.0 
0.94 (0.36 ; 2.46) 
5.20 (0.91; 29 ; 96) 
 
 
0.90 
0.06 
Marital status 
  Married or cohabiting 
  Single  
  Separated, divorced & 
widowed 
 
235 
115 
71 
 
10 
11 
5 
 
1.0 
2.24 (0.93 ; 5.45) 
1.65 (0.54 ; 5.00) 
 
1.0 
1.86 (0.67 ; 5.18) 
1.83  (0.57 ; 5.83) 
 
 
0.23 
0.30 
Occupation 
  Farmer  
  Businessman  
  Other 
 
139 
112 
169 
 
10 
6 
10 
 
1.0 
0.74 (0.26 ; 2.11) 
0.82 (0.33 ; 2.03) 
 
1.0 
0.66 (0.23 ; 1.92) 
0.71 (0.28 ; 1.82) 
 
 
0.44 
0.48 
Smoking  
 Current smoker  
 Past smoker  
 Never smoker  
 
80 
64 
277 
 
8 
4 
14 
 
1.98 (0.80 ; 4.88) 
1.24 (0.39 ; 3.88) 
1.0 
 
1.96 (0.70 ; 5.48) 
1.27 (0.37 ; 4.33) 
1.0 
 
0.19 
0.70 
Initial AFB smear grading3 
  ≤2+ 
  3+ 
 
139 
282 
 
5 
21 
 
1.0 
2.07 (0.76 ; 5.60) 
 
1.0 
1.93 (0.70 ; 5.27) 
 
 
0.20 
Initial AFB culture grading4 
  ≤2+  
  3+  
 
102 
318 
 
1 
25 
 
1.0 
8.01 (1.07 ; 59.92) 
 
1.0 
6.98 (0.92 ; 52.46) 
 
 
0.06 
BCG scar 
  No 
  Yes 
 
74 
346 
 
11 
15 
 
1.0 
0.29 (0.12 ; 0.66) 
 
1.0 
0.27 (0.11 ; 0.62) 
 
 
0.002 
HIV status 
  Negative 
  Positive 
 
255 
166 
 
18 
8 
 
1.0 
0.68 (0.29 ; 1.60) 
 
1.0 
0.84 (0.34 ; 2.06) 
 
 
0.70 
Haemoglobin  
  Non anaemic 
  Anaemic 
 
43 
378 
 
3 
23 
 
1.0 
1.15 (0.33 ; 8.98) 
 
1.0 
1.23 (0.32 ; 3.96) 
 
 
0.85 
38 
 
 
 
 
 
 
Table 8-continued
  
Converted 
Not 
converted 
 
Unadjusted 
 
Adjusted1 
  
n 
 
n 
 
OR (95% CI) 
 
OR (95%CI) 
P 
value 
White blood cell count (109cells/l) 
  <4.0  
  4.0-11.0  
  >11.0  
 
45 
356 
20 
 
1 
24 
1 
 
0.32 (0.04 ; 2.49) 
1.0 
0.74 (0.09 ; 5.76) 
 
0.37 (0.48 ; 2.82) 
1.0 
0.71 (0.09 ; 5.66) 
 
0.34 
 
0.75 
CD4 count (106cell/ml) 
  ≤200       
  201-350  
  >350       
 
90 
98 
233 
 
2 
9 
15 
 
0.34 (0.08 ; 1.54) 
1.43 (0.60 ; 3.37) 
1.0 
 
0.41 (0.09 ; 1.89) 
1.69 (0.69 ; 4.09) 
1.0 
 
0.25 
0.24 
Height5 
   Lower tertile 
  Middle tertile 
  Upper tertile 
 
139 
143 
139 
 
7 
6 
13 
 
1.20 (0.39 ; 3.66) 
1.0 
2.22 (0.82 ; 6.03) 
 
1.17 (0.37 ; 3.65) 
1.0 
2.26 (0.82 ; 6.23) 
 
0.79 
 
0.11 
Weight5 
  Lower tertile 
  Middle tertile 
  Upper tertile 
 
144 
130 
147 
 
10 
6 
10 
 
1.02 (0.41 ; 2.52) 
0.68 (0.23 ;1.92) 
1.0 
 
0.88 (0.35 ; 2.23) 
0.62 (0.21 ; 1.76) 
1.0 
 
0.79 
0.37 
BMI (kg/m2 )  
  <17 
  ≥17- <18.5 
  ≥18.5 
 
149 
93 
179 
 
8 
10 
8 
 
1.20 (0.44 ; 3.29) 
2.40 (0.91 ;6.30) 
1.0 
 
1.09 (0.39 ; 3.03) 
1.95 (0.73 ; 5.29) 
1.0 
 
0.87 
0.18 
Arm circumference5 
  Lower tertile 
  Middle tertile 
  Upper tertile 
 
132 
127 
162 
 
9 
9 
8 
 
1.38 (0.52 ; 3.67) 
1.43 (0.53 ; 3.82) 
1.0 
 
1.23 (0.46 ; 3.35) 
1.35 (0.49 ; 3.65) 
1.0 
 
0.67 
0.56 
1OR adjusted for age and sex. 
2
 OR for effect of age adjusted for sex and OR for effect of sex adjusted for age. 
3Smear grading by auramine microscopy defined as ≤2+ = 1-99 AFB per 100 fields or 1-10 AFB per field; 3+ = more  
  than 10 AFB per field. 
4
 Culture grading defined as ≤2+ = more than 1colonies; 3+ = confluent colonies. 
5Height, weight and arm circumference divided to 33.3 and 66.7 percentile and based on sex specific tertiles. 
  Lower tertile cut off ; height <158.2 for females and <167.1 for males, weight <43.1 for females and <49.7 for   
  males, arm circumference <20.6 for females  and <21.1 for males. 
  Middle tertile cut off; height 158.2-164.2 for females and 167.1-173 for males, weight 43.1-50 for females  
  and 49.7- 55.3 for males , arm circumference 20.6-23 for females and 21.1- 23.4 for males. 
  Upper tertile cut off; height ≥164.3for females and 173.1 ≥ for males, weight≥51 for females and  ≥55.4 for males, arm   
  circumference ≥24 for females and ≥ 23.5 for  males. 
  OR= odd ratio; BMI= body mass index; 95% CI= 95% confidence interval. 
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Table 9. Analysis of the predicting factors independently associated with persistent sputum smear and  
               culture positivity at the end of  the 2nd month of intensive phase1 
                                          Sputum smear conversion Smear culture  conversion 
 
Co
n
v
er
te
d 
N
o
t 
co
n
v
er
te
d Adjusted OR (95% CI) 
 
 
P 
value Co
n
v
er
te
d 
N
o
t 
co
n
v
er
te
d Adjusted OR (95% CI) 
 
 
P 
value 
Sex 
   Female 
   Male 
 
165 
229 
 
29 
93 
 
1.0 
1.92 (1.16 ; 3.18) 
 
 
0.01 
 
- 
  
- 
 
- 
Initial AFB smear grading2 
   ≤+2  
    +3 
 
146 
248 
 
26 
96 
 
1.0 
1.9 (1.17 ; 3.19) 
 
 
0.01 
 
- 
  
- 
 
- 
BMI (kg/m2 )  
  <17 
  ≥17- <18.5 
  ≥18.5 
 
126 
85 
183 
 
52 
37 
33 
 
2.18 (1.31 ; 3.64) 
2.17 (1.24 ; 3.79) 
1.0 
 
0.003 
0.006 
 
 
- 
  
- 
 
- 
BCG scar 
  No 
  Yes 
 
68 
325 
 
35 
87 
 
1.0 
0.57 (0.35 ; 0.95) 
 
 
0.032 
 
74 
346 
 
11 
15 
 
1.0 
0.28 (0.11 ; 0.62) 
 
 
0.002 
1OR adjusted for age, sex, and HIV status irrespective of their association with outcome. 
2Smear grading by auramine microscopy defined as ≤2+ = 1-99 AFB per 100 fields or 1-10 AFB per field; 3+ = more than 10 
AFB per field.   
BCG =bacillus Calmette-Guérin; CI= 95% confidence interval; OR = Odds ratio. 
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10.0 APPENDICES. 
10.1. Registration form 
PART A - (NAMES, ADDRESS, etc) 
District: _________________ DTLC:  __________________District TB No. ___________     
 
Patient’s full name: _______________________________________________________ 
 
Age: _ _ (Years)   Sex: M F    Enrolment date: _ _/_ _/200__   TB case: New    
                                                                                                                            Relapse 
Patient’s full address: Street/Area: __________________Village: ______________ 
Telephone/mobile of patient or relative: ___________ (specify relationship) _____________  
 
Full name and address of patient’s relative: _______________________________________ 
 
Full name & address of Sub-Village/Street Leader: ______________________________ 
Name of Town/City/Area: ___________________________________________ 
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PART B – (DIAGNOSIS OF TB)  
Local Microscopy: Positive Negative Date sputum collected for BMC Lab: _ _/_ _/200__ 
Date sputum collected Specimen 3+ 2+ 1+ 1-9 Negative Not done 
 1       
 2       
 3       
 
Chest x-ray:    If Done:                                  
                      Done Not done   Normal        Abnormal     Not Read 
If not done: ____________________ if abnormal:     
                                  (Specify reason)                        TB suggestive TB not suggestive 
 
PART C – (BLOOD, PHYSICAL EXAMINATION) 
Blood drawn:   Yes  No, if no specify reason:____________  
Date blood drawn:  _ _/_ _/200__ BCG-scar (TB scar): No Yes Cannot be seen 
Arm circumference: _ _, _ cm    Triceps skinfold thickness: _ _, _ mm. 
Waist circumference: _ _ _, _ cm   Hip circumference:  _ _ _, _ cm 
Height: _ _ _, _ cm      Weight: _ _ _, _ kg       Grip strength:  _ _ _, _ kg
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PART D – (QUESTIONNAIRE)  
General information: 
1. Religion?    Christian     Muslim     Orthodox          
                                     Hindu                             other, specify: ________________ 
2. Marital status?     Married     Single     Separated     Divorced                  
Widow(er)     cohabiting 
3. Tribe?   _____________________  
4. Occupation? Farmer     Fisherman  Business   Housewife   
Unemployed  Employed, skilled Employed, unskille  
                                    Other, specify: ____________________ 
Morbidity questions: 
 1. During the last one month did you have any of the following? 
a) Cough (more than 2 weeks)     No    Yes  
b) Fever         No    Yes 
c) Chest pain       No    Yes 
d) Shortness of breath      No    Yes  
e) Excessive sweating at night                             No                Yes 
f) Loss of body weight     No    Yes  Do not know 
g) Cough blood      No    Yes  
2. Have you ever been treated for TB?   No    Yes, if yes when _ _/__            
                                                                                                                                        (mm/yy).  
3. Have you ever lived together with a TB patient?   No    Yes 
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Smoking and alcohol drinking questions: 
4. Do you smoke (prior to disease/TB)?   No    Yes (skip to 4 a) If no to 4. 
Have you ever smoked?   No (skip to 5)   Yes If yes to a,     
how long time ago did you smoke (months/years)? _______ 
b) If yes to 4/4a., what do you smoke? Cigarettes Pipe    other, specify_______ 
 c) If yes to 4/4a., how many per day?   <1    1-5        6-10    
                                                                           11-15    16-20      20+ 
 d) If yes to 4/4a., how many years?   <5     6-10    10+ 
5. Do you take alcohol (prior to disease/TB)   No  (end)  Yes  
           a) Which type of alcohol did you take? (You can choose >1) Local brew Beer            
                                                                                                 Hard liquor 
           b) If you took local brew, how often?  <1/week    1-3/w    4-6/w                                                                  
                                                                         daily  
          c) If you took beer, how often?  <1/week    1-3/w    4-6/w                                                                 
                                                                         daily  
          d) If you took hard liquor, how often?  <1/week    1-3/w    4-6/w                                                                            
                                                                                     daily 
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10.2: Baseline laboratory form 
 
  PART E – (PULMONARY TB STUDY FORM: BACTERIOLOGICAL, ZTRL)     
Date sputum collected:  _ _/_ _/200__      
Date sputum received at BMC: _ _/_ _/200__        
TB case:  New  Relapse Follow up at month _______ 
 
Microscope result: At month: _____________  Positive Negative Not done  
 
Specimen 1: Smear Result  Culture Result: At month ______________ 
 
3+ 2+ 1+ Neg. Not done  3+ 2+ 1+ 1-19 Colonies Neg. Not Done Contaminated 
                         
 
45 
 
 
 
PART F: LABORATORY RESULTS FORM 
 
District / Unit Reg. No.:___________ PTB sputum status:    Positive  Negative 
   
Test Date: │__│__│ / │__│__│ / │__│__│           
DD      MM  YY 
 
HIV Rapid Tests 
 
Test Capillus Determine Conclusive 
 
ELISA 
Result  Neg 
 Pos 
 Equiv 
 Neg 
 Pos 
 Equiv 
 Neg 
 Pos 
 Equiv 
 Neg 
 Pos 
 
Tube info  
Lot/Batch No.: 
│__│__│__│__│__│__│__
│__│__│ 
Expiry date:  
│__│__│/│__│__│/│__│_
_│ 
      DD          MM          YY     
 
Lot/Batch No.: 
│__│__│__│__│__│__│__
│__│__│     
 
Expiry date:  
│__│__│/│__│__│/│__│_
_│ 
      DD          MM          YY     
  
Lab Tech  
Preparing  
    
Lab Tech  
Reading  
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Other Tests 
W.B.C 
 
Differential  
 
HemoCue 
 
HIV 
 
 
 
Test 
 
 
Total 
(mm3) 
Lym 
 
Neu Mon Eos Bas Hg 
(g/dL) 
CD4 Count 
 
Serum 
Samples 
Taken 
(√) 
 
Result 
         
Lab Tech  
Preparing Test 
    
Lab Tech  
Reading Test 
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10.3. Follow up questionnaire and laboratory form 
 
 2nd MONTHS     
PART C – (BLOOD, PHYSICAL EXAMINATION)  
Date blood drawn: ___/___/200__  
 
Height: ______, __ cm  Weight: _____, __ kg  Grip strength: _____, __ kg 
 
Arm circumference: ____. ___ cm  Triceps skinfold thickness: _____. ___ mm. 
 
Waist circumference: ____. ___ cm  Hip circumference: _____. ___  cm. 
 
PART D – QUESTIONNAIRE  
Morbidity questions: 
1. During the last one month did you have any of the following? 
a) Cough (more than 2 weeks)      No    Yes  
b) Fever          No    Yes 
c) Chest pain        No    Yes 
d) Shortness of breath       No    Yes  
e) Excessive sweating at night      No    Yes 
f) Cough blood       No    Yes  
Smoking questions: 
2. Do you smoke?       No    Yes 
 a) If yes to 2, what do you smoke?   Cigarettes Pipe    Other, 
specify _______ 
b) If yes to 2, how many per day?   <1     1-5       6-10                                         
                                                                        11-15           16-20   20+ 
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PART F: (Laboratory form results 2 and 5 months) 
Study ID. No.:_____________     Test Date: │__│__│ / │__│__│ / │__│__│           
                                                                                          DD             MM  YY 
W.B.C. 
Differential 
HemoCue HIV  
Test 
 
Total 
(mm3) 
Lym Neu Mon Eos Bas Hb 
(g/L) 
CD4 
Count 
Serum 
Samples 
Taken 
(√) 
 
Result 
 
 
        
Lab Tech 
Preparing Test 
     
Lab Tech 
Reading Test 
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10.4. Study Consent Form 
You are asked to consent for your participation in a study aimed at finding predictors of sputum 
smear conversion that are more likely to be associated with slow response/treatment failure in 
tuberculosis patients. This study is undertaken as a sub study, as part of a major study done by 
The National Institute for Medical Research (NIMR) in Collaboration with the University of 
Copenhagen, Denmark in Mwanza, Tanzania in order to improve TB treatment outcome. We are 
requesting you to participate because you have been found to have TB. Your participation might 
benefit other TB patients like you in the future. If you agree to participate you may be expected 
to answer some questions asked by clinic staff and to provide specimens for TB, and HIV 
diagnosis. 
What you are expected to do 
You will be given information about the study, and if you agree to participate you will undergo a 
brief interview and pre-test counselling for HIV. Then you will be requested to provide blood 
specimens for TB and HIV. 
Confidentiality 
The information regarding your test results will be confidential and will only be made known to 
yourself or any other person you choose to tell the results to and the clinicians treating you. Your 
name will not be mentioned or used in any papers or study reports; and only study identification 
numbers will be used.   
Benefits 
In case you are diagnosed with TB, or HIV, you will get treatment or be referred accordingly. 
Treatment for TB is provided free of charge. The same applies if you are diagnosed with HIV, 
you will be referred to the treatment and care clinic for management including provision of ARV 
as per National HIV/AIDS Treatment and Care guidelines. 
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Participation 
In case you do not want to be enrolled in the study or do not want to have your blood drawn for 
testing, that decision will not in any way interfere with your right to get TB treatment. You are 
also free to withdraw from the study anytime you feel to do so for whatever reason(s). Your 
withdrawal from the study will not affect your right to treatment 
Summary statement 
I have been told about the objectives of the study and the benefits of being included in the study. 
I have clearly understood that decision to be recruited in the study is upon me to decide and that I 
can refuse or withdraw from the study at any time and that my refusal will not interfere with my 
right to TB treatment   
Consent: 
I ------------------------------------------------------------------------------------------------------ (name of 
the client/patient) agree to participate in the study and my blood to be drawn for testing TB, and 
HIV. 
Signature of the client/patient _______________________________________  
Thumb of the client (in case not able to write) ______________________________ 
Witnessed by (name) ------------------------------------------------------------- (if patient is not able to 
write) 
Signature ______________________________ Date _______/_____/200 _____ 
Name of Clinician advising/ counselling the patient __________________________________ 
Signature of Clinician/Counsellor _____________________________________  
Date: ______/________/200_ 
NB: In the field application, this form is translated into Swahili language 
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10.5 Ethical clearance 
 
